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Abstract
Gemcitabine is commonly used for various solid organ malignancies with rarely reported cardiac side effects such as
cardiomyopathy. Pazopanib usually can cause arterial hypertension but cases of heart failure have recently been reported. We describe a case of fatal heart failure after treatment with gemcitabine and pazopanib in a 55-year-old female
with sarcoma. Patient developed left ventricular dysfunction after gemcitabine treatment and acute heart failure after 22
days of pazopanib treatment which led to death. Physicians should be aware of the cardiotoxicity risk when managing
the use of pazopanib especially in patients previously treated with other cardiotoxic drugs.
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1. Introduction

G

emcitabine is a nucleoside analog and pyrimidine antimetabolite that inhibits RNA
synthesis [1]. The most common adverse effects of
its use being myelosuppression, elevated liver
enzymes, edema, and dyspnea [2]. In regards to
cardiac complications, gemcitabine is associated
with venous thromboembolisms, digital ischemia
or necrosis, systemic capillary leak syndrome,
vasculitis, arrhythmias and thrombotic microangiopathy [3]. Although rare, gemcitabine therapy can cause cardiotoxicity in the form of acute
congestive heart failure [4]. On the other hand
pazopanib is a an oral multi-targeted tyrosine
kinase inhibitor (TKI), targeting vascular endothelial growth factor (VEGF), platelet-derived
growth factor (PDGF) and stem cell factor (c-KIT)

receptors [5,6]. It is approved for the treatment of
metastatic renal cell carcinoma (RCC) and soft
tissue sarcoma [5,6]. It is usually a well-tolerated
oral agent. The main side effects are fatigue,
nausea, diarrhoea and arterial hypertension. The
increased use of TKI agents has been associated
with recognition of a potentially fatal spectrum of
toxicities, including cardiotoxicity, sometimes
even fatal [6,7].
Here, we present a complex case of a female patient with mesenchymal tissue neoplasm, previously
treated with gemcitabine, with a fatal pazopanib
induced heart failure.

2. Case Report
A 55-year-old woman presented with persistent
right hip pain, hypotonia and paresthesia on the
right leg, for ten months in March 2019. The patient
had a smoking history of ten pack-year until her
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diagnosis, no other cardiovascular risk factor. The
patient had no other systemic disease history. Pelvic
magnetic resonance imaging (MRI) showed bone
edema and hypodense/hypointense streak on the
right hip. A guided computed tomography (CT) trucut biopsy was performed, the histopathological
examination of the tissue sample diagnosed a
mesenchymal tissue neoplasm with myoﬁbroblastic
differentiation spindle cell sarcoma. Furthermore,
diffuse lytic bone metastases and multiple pulmonary nodular-like lesions were found at 18 F-ﬂuorodeoxyglucose positron emission tomography
(PET) - CT. The mass was considered unresectable,
and gemcitabine-based systemic chemotherapy
after localized radiotherapy at lytic bone metastases
was planned. Before the systemic treatment, transthoracic echocardiography (TTE) was performed in
March 2019 and left ventricular ejection fraction
(LVEF) was measured as 60%. Gemcitabine and
zoledronic acid treatment was started. After six
months, at second follow up visit, a control TTE
showed a mild decrease in left ventricular ejection
function measured as 48%. Therefore gemcitabine
was stopped and medical therapy was optimized by
starting ramipril 2.5 mg orally once daily and bisoprolol fumarate 1.25 mg orally once daily. After one
month at follow up, considering stability of cardiological and echocardiographic status and for detection of tumor progression at control CT, pazopanib
was planned as a second line treatment. Pazopanib
was started at a dose of 800 mg once daily in
October 2019. On the 22 t h day of treatment, she
presented with palpitation, fatigue and exertional
dyspnea for one week. The blood pressure was
measured as 120/60 mmHg, the heart frequency was
112 beats per minute, the respiration rate was 18
breaths per minute, and there was no high fever.
Bilateral pretibial pitting edema was noted. There
was a third heart sound on the auscultation of the
heart and were bilateral basal crackles on the
auscultation of the lungs. She was hospitalized, and
blood tests including complete blood count, kidney
and liver function tests, C-reactive protein (PCR),
thyroid stimulating hormone, coagulation parameters, Troponin-T (two values at 0 and 2 h), N-terminal (NT)-pro hormone BNP (NT-proBNP),
arterial blood gases were obtained. Blood analyses
showed: mild normochromic normocytic anemia
(hemoglobin: 10.5 g/dl), NT-proBNP markedly
increased (10,860 pg/ml). All the other blood analyses were in normal values. The electrocardiogram
showed sinus tachycardia, nonspeciﬁc ST-T
changes. Pulmonary embolism was ruled out by
considering clinical ﬁndings, arterial blood gas
analysis, and electrocardiogram ﬁndings as a whole.

Echocardiography was performed, and LVEF was
measured as 20%. As a result, patient was admitted
to the sub intensive care unit, pazopanib-induced
heart failure (HF) was considered and pazopanib
was stopped immediately. Medical therapy has
been optimized as follows: ramipril 2.5 mg orally
once daily has been conﬁrmed, bisoprolol fumarate
has been increased to 2.5 mg orally once daily, and
spironolactone 50 mg orally once daily, furosemide
20 mg intravenous twice a day were started. The
patient's symptoms partially improved. Second
echocardiography was performed after two days,
and LVEF was measured as 30%. After an initial
apparent stabilization, the patient died during hospitalization for cardio-respiratory arrest.

3. Discussion
Our case describes a rare but fatal cardiovascular
complication of gemcitabine and pazopanib treatment. Few cases are reported in the literature about
cardiac dysfunction caused by isolated treatment
with gemcitabine [1]. Some cases reported cardiomyopathy induced by gemcitabine after treatment
with cardiotoxic anticancer drugs such as anthracyclines [8]. Generally treatment with gemcitabine
can cause supraventricular tachycardia including
atrial ﬁbrillation, especially after 18e24 h of infusion
[8]. In addiction, several case reports have demonstrated acute myocardial infarction post-gemcitabine injection secondary to drug-induced vascular
injury or endothelial damage [9e10].
Also pazopanib usually causes arterial hypertension and in a few cases heart failure [11]. Especially
several case of fatal heart failure after pazopanib are
reported [12].
In our case, gemcitabine caused left ventricular
dysfunction in a patient without cardiovascular risk
factors (only smoking); after gemcitabine treatment,
pazopanib caused fatal heart failure. Cardioprotective treatment (beta blockers and ramipril)
was started during the ﬁrst reduction of LVEF during gemcitabine treatment; gemcitabine treatment
was discontinued for 1 month in accordance with
guidelines and it was restarted 1 month later,
considering the stable value of LVEF and the necessity of oncological treatment in a patient with
advanced cancer.
Thus, gemcitabine and pazopanib-induced HF are
not very frequent but unfortunately may be fatal.
Physicians and patients should be aware of the
cardiotoxicity risk when managing the use of pazopanib, especially in patients previously treated with
other cardiotoxic drugs such as gemcitabine. This
highlights the importance of performing a complete

cardiac workup before starting this type of treatments and during follow-up.
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